Table 3.

Uncontrolled trials of RTX in SSc-ILD.

References	No of patients	Disease	RTX scheme	Follow up	Outcomes	Safety of RTX
Lafyatis et al. (25)	15	SSc	RA scheme	6 m	Stable PFTs and HRCT score	No serious AE
Daoussis et al. (26)	8	SSc	Lymphoma scheme	2 y	Improved PFTs and HRCT score	3 serious infections, 2 infusion reactions
Smith et al. (27)	8	SSc	RA scheme	2 y	Increased FVC, stable DLCO	5 serious AE/1 death
Bosello et al. (28)	20	SSc	RA scheme	2 y	Stable PFTs and HRCT score	4 serious AE
Fraticelli et al. (29)	15	SSc	RA scheme	6 m	Improved FVC, stable DLCO, Imroved HRCT	No serious AE
Vilela et al. (30)	10	SSc	RA scheme	6 m	Stable PFTs	–
Sari et al. (31)	15	SSc	Ra scheme	Variable	Stable PFTs	No serious AE